Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28564071 | 0.86 | LMNA (0.35) | LMNAALDH1A1USP2KDM4EDUSP3 | |
| SCHEMBL27886174 | 0.83 | ALDH1A1 (0.31) | LMNAALDH1A1 | |
| SCHEMBL2912805 | 0.82 | — | — | |
| SCHEMBL15887085 | 0.82 | — | — | |
| SCHEMBL28229216 | 0.81 | SMN1; SMN2 (0.50) | LMNAUSP2SMN1; SMN2 | |
| SCHEMBL15887074 | 0.81 | USP2 (0.33) | USP2SMN1; SMN2 | |
| SCHEMBL159440 | 0.81 | SMN1; SMN2 (0.50) | LMNAUSP2SMN1; SMN2 | |
| SCHEMBL14047309 | 0.81 | USP2 (0.33) | USP2SMN1; SMN2 | |
| SCHEMBL26661989 | 0.81 | SMN1; SMN2 (0.50) | LMNAUSP2SMN1; SMN2 | |
| SCHEMBL27832027 | 0.80 | LMNA (0.36) | LMNAALDH1A1USP2KDM4EDUSP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106456545-A | Immunogenic liposomal formulation | 葛兰素史密丝克莱恩生物有限公司 | 2017-02-22 | — | — | CN | claimed |
| WO-2016014539-A1 | PHOSPHONIC ACID COMPOUNDS AND SCREENING METHOD | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2016-01-28 | — | — | WO | claimed |
| CN-105209041-A | Novel respiratory control modulating compounds and methods of use thereof | GALLEON PHARMACEUTICALS INC | 2015-12-30 | — | — | CN | claimed |
| US-20250325569-A1 | COMPOSITIONS AND METHODS OF MAKING AND USE THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2025-10-23 | — | — | US | disclosed |
| CN-118852530-A | Phosphoglyceride-based polymer and preparation method and application thereof | 湖北工程学院 | 2024-10-29 | — | — | CN | disclosed |
| WO-2023200968-A1 | COMPOSITIONS AND METHODS OF MAKING AND USE THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2023-10-19 | — | — | WO | disclosed |
| CN-110746518-A | Preparation method of high-purity ganoderma lucidum polysaccharide | 西藏天虹科技股份有限责任公司 | 2020-02-04 | — | — | CN | disclosed |
| CN-110452262-A | The synthetic method of platelet activating factor (PAF) analog | AMTECH BIOENGINEERING LTD INC | 2019-11-15 | — | — | CN | disclosed |
| CN-104367997-B | Adjunvant composition comprising nonionic isotonic agent | 葛兰素史密丝克莱恩生物有限公司 | 2019-01-22 | — | — | CN | disclosed |
| CN-108602866-A | Expression and folding in CD-RAP preparation process is improved by using CD-RAP precursor proteins | 生命制药有限责任公司 | 2018-09-28 | — | — | CN | disclosed |
| CN-107735383-A | Cement tile adhesive composition containing cross-linked cellulose ether for mortars with enhanced gel strength | 陶氏环球技术有限责任公司 | 2018-02-23 | — | — | CN | disclosed |
| CN-1151777-C | Preparation for transport of active substance across barriers | �����ɷ� | 2004-06-02 | — | — | CN | disclosed |
| CN-1283107-A | Methods of developing, testing and using complexes of macromolecules and complex aggregates for improved payload and controllable dissociation/association rates | IDED INNOVATIVE DERMALE APPLIK (DE) | 2001-02-07 | — | — | CN | disclosed |
| CN-1234736-A | Preparation for transport of active substance across barriers | IDEA INNOVAT DERMALE APPL GMBH (DE) | 1999-11-10 | — | — | CN | disclosed |
| US-5130308-A | Indole derivatives as anticarcinogenic agents | ASTA PHARMA (DE) | 1992-07-14 | — | — | US | disclosed |
| US-4992553-A | Treatment of hormone dependent tumors | ASTA PHARMA AKTIENGESELLSCHAFT (DE) | 1991-02-12 | — | — | US | disclosed |
| US-4847297-A | AIDS TREATMENT | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1989-07-11 | — | — | US | disclosed |
| US-4730068-A | SPECIAL EFFECT ON BREAST CANCER | ASTA-WERKE AKTIENGESELLSCHAFT (DE) | 1988-03-08 | — | — | US | disclosed |
| US-4704464-A | CHELATE COMPOUNDS | ASTA-WERKE AKTIENGESELLSCHAFT CHEMISCHE FABRIK (DE) | 1987-11-03 | — | — | US | disclosed |
| US-4598091-A | (1,2-diphenyl)-ethylenediamine)-platinum (II) complex compounds | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1986-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325569-A1 | COMPOSITIONS AND METHODS OF MAKING AND USE THEREOF | PGLS, PLA2G2C, PPA1 | LMNA 3836/4885ALDH1A1 1878/4885USP2 3814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.